Remove Blogging Remove Development Remove Funding Remove Layoffs
article thumbnail

Should Startups Announce Their Funding?

Both Sides of the Table

Understanding “The Funding Angle” I sit at enough board meetings to hear conflicting advice given to entrepreneurs about how to handle PR and announcements at startups. Is Funding a Worthy Announcement? There are reasons you may delay funding announcement but rarely reasons not to announce. But trust me on this.

Startup 355
article thumbnail

Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More

Xconomy

military’s high-tech think tank DARPA described Safe Genes, a new program to fund safety measures that can be built into genome editing technology or counter its potential wayward effects. The funding could be as much as $100 million, and the first grants will be announced in 2017. Shares immediately fell more than 40 percent.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A Post Startup Execs Should Forward to Your Spouse or Partner. 12 Tips for Making it Work

Both Sides of the Table

Anyway, as I winnowed my way through the comments section of my blog post on relationships I realized my own wife has posted a response! Respect and develop a positive working relationship with his co-workers. As she is quite accomplished in her own right so I take her opinion very seriously. Work Travel isn’t fun.

Tips 418
article thumbnail

Biotech Roundup: Moonshots, Pink Slips, Gilead, Brexit & More

Xconomy

If you want fireworks this weekend, you can either celebrate the 4th of July or watch the latest post-Brexit political developments in Britain. The technology was funded by the Department of Defense and comes from MIT’s Lincoln Lab. If you want a roundup of the week’s biotech’s news, read on.

article thumbnail

Biotech Roundup: Hellos, Goodbyes, “Cures” Delays And Trial News

Xconomy

” —Company funding news: Tesaro (NASDAQ: TSRO ) of Waltham, MA, said it took advantage of positive Phase 3 data to raise $409 million in a secondary stock sale…Protagonist Therapeutics, based in Milpitas, CA, has filed for a $75 million initial public offering. million in funding, according to a regulatory filing.

News 40
article thumbnail

Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More

Xconomy

After guiding the CRISPR-Cas9 genome-editing startup from scientific breakthrough toward the development of a potential cutting-edge medicine, slogging victoriously through a legendary patent fight , and reaching the cusp of an historic clinical trial , the well-traveled Bosley is cutting out, the company said Tuesday.

Guide 63